Answers are grounded in this paper and cite their sources.
Advanced recurrent NSCLC has a poor prognosis with limited effective treatment options. The oncofetal antigen 5T4 is frequently overexpressed across multiple solid tumors, including NSCLC, with limited expression in healthy adult tissues, making it an ideal therapeutic target. XB010 is a site-specific antibody-drug conjugate (ADC) with a monomethyl auristatin E (MMAE) payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4 using a tandem-cleavage linker. Upon binding to 5T4 on the surface of tumor cells, XB010 is internalized, and the linker is enzymatically cleaved to release MMAE, which also has bystander activity by diffusing into surrounding tumor cells.
No takes yet. Share an insight, caveat, or question.
Salkeni et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: